Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $10.03, up 1.01% on the session, giving a market capitalisation of $890.4M. On trailing twelve-month figures it carries a trailing P/E of -2.99, a net margin of -411.2%. Its beta of 0.38 implies it has historically moved less than the broad market.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology, Inc. is most often compared with the following Healthcare names: